Bispecific antibody + new stem cell transplantation Janssen collaborates to develop a combination therapy for blood cancer

On July 8, 2021, Vor Biopharma announced that it has reached a cooperation agreement with Janssen Biotech, a subsidiary of Johnson & Johnson

In cell therapy, the eHSC platform developed by Vor has an innovative mode of action, and is often used in combination with other targeted therapies for the treatment of tumors

▲Anti-cancer targeted therapy may accidentally injure healthy cells (Image source: Vor official website)

On the eHSC platform, researchers use CRISPR/Cas9 gene editing technology to modify stem cells to knock out genes encoding target proteins

▲The working mechanism of the eHSC platform (picture source: Vor official website)

Take VOR33, an investigational therapy in the Vor R&D pipeline, as an example.

Note: The original text has been deleted

Reference materials:

[1] Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML).